Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thoratec has received FDA approval of its premarket approval application, allowing the use of its HeartMate II Left Ventricular Assist System as a bridge-to-transplantation in patients suffering from advanced-stage heart failure.
Subscribe to our email newsletter
The approval follows a successful clinical trial involving more than 450 bridge-to-transplantation (BTT) patients, including those enrolled under continued access protocols, and a unanimous recommendation for approval from the FDA Circulatory System Devices Advisory Panel in November, 2007.
The approval allows the HeartMate II to be used to treat small patients (BSA < 1.5) based on body habitus if the treating clinician believes that the patient could benefit from the device. In addition, Thoratec will conduct a post-market study that includes a concurrent comparator. The study will follow 169 HeartMate II patients until outcome, or one year - whichever comes first - and gather data regarding survival, adverse events, patient gender, small patients and anticoagulation levels. Gary Burbach, president and CEO of Thoratec, said: "The HeartMate II is the first continuous flow device to receive FDA approval for this intended use in the US, representing a milestone in the treatment of advanced-stage heart failure patients and for the clinicians who treat them."